Navigation Links
Quigley Corporation Announces Final Results of Quigley Pharma's Phase IIb Study
Date:7/22/2009

iminary analysis of the lack of adequate primary and secondary end point data indicates that the results may have been attributed to fewer then expected evaluable patients due to a shortage of drug and a high number of patients terminated early due to a lack of compliance with application and usage protocols.

"We have recently hired an independent consultant to conduct a thorough review of the entire research and development portfolio of potential products in the Quigley Pharma pipeline," said Ted Karkus, CEO. "We will wait for this review to be completed before determining the next steps in the development of QR-333 and other formulations."

All required end of study regulatory and reporting documentation and procedures will be completed. Consistent with previous announcements and pending the full review of the product portfolio, the Company will continue to consider licensing, partnering or collaborative relationship opportunities to further the development and potential commercialization of the QR-333 candidate and other formulations.

The ADA estimates that neuropathy occurs in up to 60-70% of diabetics, and an estimated 5 million Americans are affected by diabetic peripheral neuropathic pain. The World Health Organization estimates that more than 171 million people have diabetes worldwide, a figure that is expected to rise to 366 million by 2030.

About the study:

Methodology:

This was a double-blind, randomized, parallel-group, placebo controlled study conducted at 22 sites with 1 to 27 patients randomized per site. Patients between the ages of 18 and 70 years with a diagnosis of diabetes and symptoms of peripheral neuropathy were eligible for enrollment into the study. Eligible patients were randomized to 1 of 2 groups each applying study cream topically to the feet three times daily (tid) with placebo or QR-333 for
'/>"/>

SOURCE Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
2. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
3. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
4. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
5. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
6. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
7. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
8. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
9. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
10. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
11. The Quigley Corporation Issues Open Letter to Stockholders; Urges Stockholders to Reject Dissident Ted Karkus Solicitation Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 02, 2015 CRN International has been ... Platform to Employment , a Connecticut state program that takes ... and place them at appropriate companies. , Platform to Employment ... with the Connecticut Department of Labor. CRN, a 40-year-old radio ... the program, is being recognized for its “hard work and ...
(Date:6/2/2015)... COLUMBIA, Md. (PRWEB) June 02, 2015 ... of its LCMS-8060 triple quadrupole mass spectrometer. The ... series, the LCMS-8060 combines Shimadzu’s proprietary ultrafast technologies ... unparalleled combination results in outstanding data quality and ... and routine applications. , The LCMS-8060 features new ...
(Date:6/2/2015)... Zambia (PRWEB) June 02, 2015 ... businesses, today opened a new seed warehouse and office ... and meet farmer demand for both local and export ... , “Zambia could emerge as the breadbasket for ... said Worede Woldemariam, East and South Central Africa senior ...
(Date:6/2/2015)... 2015 PhishLine, LLC today announced ... Swenson Drive, Suite 125 in Waukesha, Wisconsin 53186. ... new base of operations for PhishLine’s current corporate ... growth. , Mark Chapman, Founder and President, commented ... as enterprise customers adopt our market leading service ...
(Date:6/2/2015)... a popular online store selling celebrity inspired fashion products, ... dresses. The company carries more than 1000 styles of ... a wide variety of summer events like wedding and ... quality trendy special occasion dresses and accessories. ... and cotton. Their products feature a wide range of ...
Breaking Medicine News(10 mins):Health News:CRN Named Company Partner of the Year by CT Employment Program 2Health News:Shimadzu’s New LC-MS/MS Provides Superior Speed and Sensitivity for the Utmost in Quantitative Detection and High-Speed Analysis 2Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 2Health News:Investing in Infrastructure Critical to Advancing Food Security in Zambia 3Health News:PhishLine, LLC Announces New Corporate Headquarters 2
... 2012 Testosterone, the primary male sex hormone, appears ... its effects have remained unclear. Nicole Carrier and Mohamed ... to elucidate these mechanisms. They,ve discovered that a ... in memory formation and regulation of stress responses, plays ...
... Society (ERS) and the European Centre for Disease Prevention ... Standards for Tuberculosis Care (ESTC). The 21 patient-centred standards ... ensure optimal diagnosis, treatment and prevention of tuberculosis (TB) ... in the EU/EEA in 2010 clearly showing that TB ...
... in men with prostate cancer before prostatectomy helped to reduce ... cancer, according to the results of a phase II study. ... at the Princess Margaret Hospital, University Health Network in Toronto, ... 2012, held here March 31 - April 4. Metformin ...
... FRIDAY, March 30 (HealthDay News) -- Cold conditions may affect ... research studies, a new study suggests. Researchers from the ... drugs tested on mice that were housed in chilly temperatures ... because being cold triggers changes in mice,s immune function and ...
... FRIDAY, March 30 (HealthDay News) -- While unseasonably warm weather ... thrilled with the early arrival of spring. Arriving along ... hay-fever sufferers sneezing at least a few weeks sooner than ... season starting early, but the pollen counts are breaking records. ...
... , FRIDAY, March 30 (HealthDay News) -- The declining ... a specialty is cause for concern because there,s already ... downward trend has occurred for the past six years, ... Medical schools need to provide more information and training ...
Cached Medicine News:Health News:Exploring the antidepressant effects of testosterone 2Health News:Towards TB elimination: ECDC and ERS introduce new guidelines on tuberculosis care in Europe 2Health News:Metformin appeared to slow prostate cancer growth 2Health News:For Better Mouse Studies, Let Them Nest 2Health News:Warm Weather Triggers Early Allergy Season 2Health News:Warm Weather Triggers Early Allergy Season 3Health News:Fewer U.S. Med Students Choose Psychiatry: Report 2
(Date:6/2/2015)... ANGELES , June 2, 2015  CytRx Corporation ... company specializing in oncology, today announced that it has ... pending in the Delaware Court ... the Company,s current and former directors and officers, and ... The lawsuit, captioned In re CytRx Corp. Stockholder ...
(Date:6/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jrlgdj/electrophysiology ) has ... by Product {Diagnostic Catheter (Conventional, Advanced, Ultrasound)), Ablation ... Generator, ICE, X-ray)) & Indication (AF, VT, WPW) ... their offering. The global electrophysiology (EP) ... CAGR of 10.3% from 2014 to 2019 ...
(Date:6/2/2015)... , Minn. and WELLESLEY, Mass., June 2, 2015 /PRNewswire/ ... principal owner, Ampersand Capital Partners (Ampersand), announced the ... operation of Array BioPharma Inc. (Array).  Accuratus was ... Eagan, MN acquired Microtest ... GLP analytical and microbial testing services to the ...
Breaking Medicine Technology:CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 3Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma 2Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma 3
Inquire...
... The new Finnpipette Focus ... specifically to combine ergonomics with ... interchangeable handle plate offers a ... sizes. The new shorter tip ...
... pipette is ideal for repeated ... Fixed volume FInnpipettes offer the ... other Finnpipette Digital pipettes: ... (1-40ul), Soft-touch tip ejection, Safety ...
100L...
Medicine Products: